{"id":11245,"date":"2020-05-26T00:00:00","date_gmt":"2020-05-26T00:00:00","guid":{"rendered":"https:\/\/www.cancerresearch.org\/media-room\/rapid-growth-in-global-development-of-cancer-cellular-immunotherapies-highlighted-by-latest-report-from-cancer-research-institute-and-globaldata\/"},"modified":"2022-07-13T04:10:45","modified_gmt":"2022-07-13T04:10:45","slug":"cancer-cellular-immunotherapies-global-growth","status":"publish","type":"cri_news","link":"https:\/\/www.cancerresearch.org\/es\/media-room\/cancer-cellular-immunotherapies-global-growth","title":{"rendered":"Rapid Growth in Global Development of Cancer Cellular Immunotherapies Highlighted by Latest Report from Cancer Research Institute and GlobalData"},"content":{"rendered":"\n

The Cancer Research Institute (CRI) and GlobalData announced today the publication of an updated report on clinical development of cancer cellular immunotherapy trends that leveraged data from GlobalData\u2019s Pharma Intelligence Center platform. The 2020 report, \u201cCancer cell therapies: The clinical trial landscape,\u201d was published in Nature Reviews Drug Discovery<\/em><\/a>,<\/em> following the second report published in May 2019.<\/p>\n\n\n\n

The new report, which includes data as of March 2020, highlights the rapid growth in the development of cellular immunotherapy in both the preclinical and clinical development stages compared to the 2019 report. Specifically, the current global cellular immunotherapy pipeline includes 1,483 active agents \u2013 472 more in development than one year ago.<\/p>\n\n\n\n

A majority of cellular therapies (667) currently disclosed to be in development are autologous, which involves using a person’s own cells, but the greatest percent increase has been in preclinical (73.8% increase from 2019) and phase 1 (90.9% increase from 2019) development of disclosed allogeneic (off-the-shelf) therapies.<\/p>\n\n\n\n

\u201cWhile it is very likely that the momentum for clinical trials for cellular immunotherapies in oncology will be impacted by the COVID-19 pandemic, advances in cellular immunotherapy remain important as some of these agents, such as Natural Killer cells, are being investigated in clinical trials to potentially repurpose them to treat novel coronavirus patients,\u201d said Vanessa Hubbard-Lucey, PhD, MBA, director of the CRI Venture Fund and Anna-Maria Kellen Clinical Accelerator and co-author of the cancer cellular immunotherapies landscape publication.<\/p>\n\n\n\n

CAR-T cell therapies not only dominate the cancer cell therapy pipeline, but also have shown the largest increase of 290 agents in development this year compared to the increase of 164 agents last year \u2013 a growth of 77%.<\/p>\n\n\n\n

\u201cIt is very important that growth in CAR-T cell therapies was seen in phase 1 and phase 2 assets as well. This gives us a hope that some of these therapies will progress in phase 3 and eventually be available for treating cancer patients,\u201d commented Revati Tatake, PhD, global director of databases and analytics at GlobalData. \u201cAnother very encouraging sign is to see increase in novel T cell technology-based therapies in 2020 as compared to the 2019 pipeline, with three assets in phase 3 in the 2020 pipeline.\u201d<\/p>\n\n\n\n

The United States and China dominate the cancer cellular immunotherapy pipeline and clinical trials. The two countries have a similar number of cellular immunotherapy agents in development (600 and 508, respectively), but China has more trials in progress than the United States (871 vs. 718).<\/p>\n\n\n\n

\u201cIt is encouraging to see such notable upward trends this year in the types of therapies in the pipeline, the proteins that are being targeted for blood and solid cancers, and geographies where these therapies are being developed,\u201d added Hubbard-Lucey.<\/p>\n\n\n\n

\u201cWe are pleased to collaborate with the Cancer Research Institute to contribute essential data to the 2020 report on the landscape of drug development and clinical trials of cancer cellular immunotherapies, which represents the largest number of active agents in development in the field of immuno-oncology,\u201d added Tatake, \u201cIt\u2019s exciting to see that this field is increasingly exploring more off-the-shelf therapies as an additional option to benefit a wider patient population.\u201d<\/p>\n\n\n\n

Other key findings from the 2020 report, include:<\/p>\n\n\n\n